AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Celltech forms alliance with Amgen for research, development.(Celltech Group PLC)(Brief Article)
2002 JUN 20 - (NewsRx.com & NewsRx.net) -- Celltech Group plc (CLL) announced an agreement with Amgen (AMGN) for the research, development and global commercialization of novel treatments for osteoporosis, utilizing Celltech's proprietary antibody fragment technology.
Osteoporosis is a degenerative bone disease estimated to affect one-third of women ages 60 to 70, and two-thirds of women ages 80 or older. Current treatments primarily halt loss of bone density, but do not reverse the effects of osteoporosis. Through extensive genetic research carried out at its Seattle research center, Celltech has identified a protein involved in the regulation of bone deposition. It is believed that by inhibiting this protein, known as Sclerostin, with a high affinity antibody fragment, bone loss in osteoporosis patients may be reversed.
Key terms of the agreement are as follows:
* Amgen receives exclusive worldwide rights to develop ...
- Celltech Group Plc and BioReliance Corp. (Pharmaceuticals in Brief).(Brief...
- Magazine article from: Chemical Market Reporter April 1, 2002 700+ words
CELLTECH GROUP PLC and BioReliance Corp. have established a multiyear manufacturing...in which BioReliance will manufacture and supply clinical grade, antibody fragment-based drugs to Celltech. BioReliance will support three product...
- Seattle Genetics Achieves Milestones Under Antibody-Drug Conjugate...
- Press release article from: Business Wire June 17, 2003 700+ words
...ADC) collaboration agreement with Celltech Group (LSE:CCH) (NYSE:CLL), which...diseases utilizing our antibody and antibody fragment technology alongside Seattle Genetics...its ADC technology with Genentech, Celltech Group and Protein Design Labs. More information...
- Celltech Group plc Oncology Pipeline Update.
- Press release article from: PR Newswire June 16, 2003 700+ words
Celltech Group plc is today providing a comprehensive...extremely high affinity PEGylated antibody fragment targeting the VEGF pathway. Data...PDGF-beta receptor PEGylated antibody fragment, has recently completed a small...
- Celltech Group plc Annual General Meeting.
- Press release article from: PR Newswire May 25, 2000 700+ words
...LONDON, May 25 /PRNewswire/ -- Celltech Group plc (NYSE: CLL), one of the largest...870 is a potent PEGylated anti-TNF antibody fragment, which is being developed for the...a PEGylated anti-PDGF receptor antibody fragment, is being evaluated as a novel approach...
- Manufacturing, supply agreement struck with Biochemie.(and Celltech Group PLC)
- Newspaper article from: Immunotherapy Weekly November 6, 2002 700+ words
...amp; NewsRx.net) -- Celltech Group plc (CLL) announced that...supply to Celltech PEGylated antibody fragment-based drugs. Celltech...portfolio of PEGylated antibody fragment based development products...now has four PEGylated antibody-fragment based products in ...
- CELLTECH, BMS STOP DEVELOPMENT OF NSCLC PRODUCT AFTER PHASE II.(Celltech Group...
- Magazine article from: BIOWORLD Today Coghill, Kim June 17, 2003 700+ words
...Coghill , Washington Editor Celltech Group plc's partner, Bristol...high-affinity PEGylated antibody fragment targeting the VEGF (vascular...beta receptor PEGylated antibody fragment. CDP 791 will enter Phase...an anti-TNF-alpha antibody fragment for rheumatoid ...
- Pharmacia, Celltech in Major Drug Pact.(Pharmacia Corp., Celltech Group PLC,...
- Magazine article from: Chemical Market Reporter KRAUSE, CAREY March 12, 2001 700+ words
...following Pharmacia Corporation's agreement to in license Celltech Group's anti TNF-alpha compound (CDP 870), which is being...to moderate rheumatoid arthritis. Also, CDP 870 is an antibody fragment, making it cheaper and easier to make. However, further...
- Celltech Group plc Preliminary Announcement of Results For the Year Ended 31st...
- Press release article from: PR Newswire March 14, 2001 700+ words
...registration or mid/late stage development are highlighted below: -- CDP 870 -- Celltech's third generation anti-TNFa antibody fragment is being evaluated in an international Phase IIb dose-ranging study in rheumatoid arthritis, conducted in over 200 patients...